RapidAI acquires EndoVantage to expand scope to cerebral aneurysm
By Akshay Kedari  Date: 2020-06-10

RapidAI acquires EndoVantage to expand scope to cerebral aneurysm

RapidAI, an advanced stroke imaging leader, has recently announced the acquisition of a medical stimulation technology developer, EndoVantage. The deal will enable RapidAI to expand its scope from ischemic stroke, hemorrhagic stroke to cerebral aneurysm.

EndoVantage develops a comprehensive cerebral aneurysm management platform, Find, Track & Treat™. Cerebral aneurysm is a neurological condition, with nearly 1 in 50 U.S. people suffering from unruptured cerebral aneurysm. One rupture leads to brain hemorrhages among patients in every 18 minutes.

RapidAI unveiled Rapid ICH in 2019, which adopts the latest AI technology to help clinicians remain notified of possible hemorrhages. EndoVantage has developed a computational platform at Mayo Clinic & Arizona State University that offers a comprehensive management for cerebral aneurysm. It automates the entire workflow, including the initial assessment, treatment planning, and growth monitoring. It deploys MRA and CTA scans to help physicians discover and track aneurysm progression as well as leverages the data from the 3D rotational angiograms to offer detailed 3D models of the vasculature of the patients. Additionally, it provides room for presurgical planning for repairing aneurysm.

According to Don Listwin, RapidAI’s CEO, the company can strengthen its position as a cerebrovascular imaging leader across the globe through the recent acquisition deal. By leveraging the technology developed by EndoVantage, it can offer a complete product portfolio, encompassing aneurysm, hemorrhagic stroke, and ischemic stroke to the hospitals. These end-to-end solutions can help enhance patient outcomes across a wide spectrum of cerebrovascular disorders.

The Rapid® platform includes:

  • Rapid ICH: Automatically triages CT scans that are non-contrast to rapidly detect brain hemorrhages with a 95% sensitivity and 94% specificity.
  • Rapid ASPECTS: Identify early ischemic change areas automatically on non-contrast CT scans, predicting irreversible injury.
  • Rapid CTA: Assess reduced blood flow regions automatically to alert, locate, and identify stroke teams in the presence of LVOs (large vessel occlusions).
  • Rapid CTP: Accurately quantifies reduced transit time, cerebral blood volume, and cerebral blood flow.
  • Rapid MRI: Quantify delayed contrast arrival and brain areas with the low ADC values.

Source credit:

https://www.rapidai.com/press-release/rapidai-acquires-endovantage

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Fibonacci Brands acquires Darwin from Harvest Health & Recreation
Fibonacci Brands acquires Darwin from Harvest Health & Recreation
By Akshay Kedari

Fibonacci Brands has recently announced the acquisition of Darwin from Harvest Health & Recreation (HARV.CN) as its foundation brand. Fibonacci is a leading player in the international cannabis industry. According to James George, founder of Fib...

GVN adds EVIT Center and Chumakov as its new Centers of Excellence
GVN adds EVIT Center and Chumakov as its new Centers of Excellence
By Akshay Kedari

The Global Virus Network (GVN), an international coalition of medical virologists, has recently announced the addition of Australian and Russian researchers. GVN is adding the Center for EVIT (Emerging Viruses, Inflammation & Therapeutics) of th...

Wind Point Partners takes over RTIC to expand business portfolio
Wind Point Partners takes over RTIC to expand business portfolio
By Akshay Kedari

American private equity firm, Wind Point Partners has recently signed an acquisition deal with the one of the biggest direct-to-consumer (D2C) eCommerce providers of drinkware, RTIC. Reportedly, RTIC is Wind Point’s third acquisition of a famil...

Novartis reveals positive data from Phase III ORION trials of inclisiran
Novartis reveals positive data from Phase III ORION trials of inclisiran
By Akshay Kedari

Swiss multinational pharmaceutical firm, Novartis has recently announced results from its Phase III ORION-10 and -11 studies that focus on assessing the individual responses of patients on lowering low-density lipoprotein cholesterol (LDL-C) with inc...

Medtronic to acquire Companion Medical to expand diabetes business
Medtronic to acquire Companion Medical to expand diabetes business
By Akshay Kedari

Medtronic plc, the global leader in medical technologies, has reportedly announced that it is planning to acquire insulin pen manufacturer Companion Medical. The acquisition gives Medtronic access to Companion Medical’s ‘InPen’, wh...